Physician profile
Amanda Berg
NPI 1699984062
$3,505.83
in general payments reported to CMS, 2019-2025
25 companies · $268 in 2025
The $268 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,731 · 2020: $546 · 2021: $371 · 2022: $133 · 2023: $135 · 2024: $322 · 2025: $268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $725.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $725.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $470.95 | 2019-2025 | Breztri, Farxiga |
| Pfizer INC. | $436.47 | 2019-2024 | |
| Novo Nordisk INC | $428.15 | 2019-2024 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $377.81 | 2019 | |
| Merck Sharp & Dohme LLC | $318.83 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $191.98 | 2019-2022 | |
| Exact Sciences Corporation | $137.72 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbvie INC. | $135.00 | 2019-2024 | |
| Glaxosmithkline, LLC. | $122.90 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Teva Pharmaceuticals USA, INC. | $110.51 | 2019-2020 | |
| Angiodynamics, INC. | $106.25 | 2025 | Auryon Laser System 100-120 Vac |
| Kvk-Tech, INC. | $98.58 | 2019-2021 | |
| Amgen INC. | $97.83 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $92.17 | 2019-2020 | |
| Terumo Medical Corporation | $62.50 | 2025 | R2p Misago, Azur Cx Detachable |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $57.69 | 2019-2024 | Zepbound |
| Allergan, INC. | $55.80 | 2019 | |
| Sanofi-Aventis U.S. LLC | $49.86 | 2019-2021 | |
| Gilead Sciences, INC. | $34.66 | 2019-2020 | |
| Mdd US Operations, LLC | $25.87 | 2019 | |
| Edwards Lifesciences Corporation | $24.05 | 2024 | |
| Radius Health, INC. | $20.08 | 2019 | |
| Braintree Laboratories, INC. | $19.28 | 2019 | |
| Novartis Pharmaceuticals Corporation | $16.71 | 2024 | |
| Astellas Pharma US INC | $14.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Berg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.